Cite
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
MLA
Barve, Minal A., et al. “A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology, vol. 41, June 2023, p. 2524. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.2524.
APA
Barve, M. A., Tolcher, A. W., Carvajal, R. D., Izar, B., El-Khoueiry, A. B., Hanna, D. L., Tarhini, A. A., Whitman, E. D., Bhatia, S., Davar, D., Lutzky, J., Taylor, M. H., Tello, M., Rosenthal, K., Danielyan, A., Yip, W. K., Song, J., Savitsky, D., Chand, D., & Grossman, J. E. (2023). A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors. Journal of Clinical Oncology, 41, 2524. https://doi.org/10.1200/JCO.2023.41.16_suppl.2524
Chicago
Barve, Minal A., Anthony W. Tolcher, Richard D. Carvajal, Benjamin Izar, Anthony B. El-Khoueiry, Diana L. Hanna, Ahmad A. Tarhini, et al. 2023. “A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology 41 (June): 2524. doi:10.1200/JCO.2023.41.16_suppl.2524.